Dr. Howard A. Liebman, MD

Dr. Liebman practices at USC Norris Cancer Hospital in Los Angeles, California.

Dr. Liebman's NPI, 1134159775, was assigned on July 3, 2006. Dr. Liebman graduated from Keck School of Medicine of USC in 1973. Dr. Liebman holds California license G28178.

Dr. Liebman's primary practice is USC Norris Cancer Hospital, at 1441 Eastlake Ave, Los Angeles, CA.

Dr. Liebman's primary practice is USC Norris Cancer Hospital in Los Angeles, California. Dr. Liebman is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Liebman to 1 more hospital, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Liebman practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Liebman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Liebman is licensed in California.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT), immune deficiency disease, lymphoma, neutropenia and purpura and thrombocytopenia among the conditions Dr. Liebman treats.

CMS data shows 167 Medicare services from Dr. Liebman across 3 procedure codes in 2024, for 113 Medicare patients. Medicare paid $10,478 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 113 Medicare patients who saw Dr. Liebman in 2024. The largest group is 65 to 74, with 52 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 2.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Liebman's median patient age at 66, with 48% women.

In 2024, Dr. Liebman wrote 179 Medicare Part D claims for 38 patients. 46% of them were for generic drugs. CMS names the drug for 118 of them, across 5 drugs with 11 or more claims each, at $53,766 in total drug cost. In 2023, CMS named 143 claims across 5 drugs.

Dr. Liebman accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 114 papers to Dr. Liebman, published from 2007 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Venous Thromboembolism, Purpura, Thrombocytopenic, Idiopathic and Acquired Immunodeficiency Syndrome. Dr. Liebman has published most often in Blood. Dr. Liebman's most frequent co-authors are James B. Bussel, MD, Ilene C. Weitz, MD and Casey L. O'Connell, MD.

Dmand AI links Dr. Liebman to 3 clinical trials. 3 are still active or recruiting. Conditions studied include Purpura, Thrombocytopenic, Idiopathic and Purpura, Thrombocytopenic. Open Payments lists research payments to Dr. Liebman that name 1 trial.

CMS Open Payments shows 424 general payments to Dr. Liebman from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 68% of the total. Sanofi and Genzyme US Companies paid the most, $98,484. It also lists 1 research payment totaling $250 in 2025, naming 1 clinical trial.

Dmand AI lists 3 awards for Dr. Liebman, most recently Donald I Feinstein chair in Hematology in 2017.

Dr. Liebman graduated from Keck School of Medicine of USC in 1973.

Dr. Liebman is in network with 7 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.